trevitherapeutics.comCrawled Oct 24, 2026
Trevi Therapeutics is currently conducting the following clinical trials of the investigational therapy nalbuphine ER. For eligibility criteria and enrollment information, please visit the links below or www.clinicaltrials.gov.
Haduvio targets both central and peripheral nervous system pathways to manage chronic cough, acting as a kappa agonist and mu antagonist (KAMA).
The Phase 3 clinical trials OCEAN-1 and OCEAN-2 are seeking to understand an investigational treatment, oral nalbuphine ER (extended-release) (NAL ER), and its potential effects on chronic cough in patients with IPF.
Wijsenbeek-Lourens et al., presentation at European Respiratory Society Congress (2026)
195 Church Street, 16th Floor New Haven, CT 06510 map
Trevi Therapeutics focuses on scientific and pharmaceutical development for chronic cough, an area with no FDA-approved treatments.
Trevi Therapeutics’ team collaborates to advance Haduvio (oral nalbuphine ER) for patients with chronic cough.
Trevi Therapeutics’ Board of Directors includes experienced life science executives who guide initiatives in medicine development and stockholder returns.
The Trevi leadership team is highly engaged and experienced in life science clinical development and building value.
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER) to treat chronic cough by targeting the central and peripheral cough reflex arc.
Trevi Therapeutics seeks commercial partners to help bring relief to patients with chronic cough.
195 Church Street, 16th Floor New Haven, CT 06510
Trevi Therapeutics is dedicated to developing Haduvio (oral nalbuphine ER) for chronic cough conditions.
Trevi Therapeutics’ Consumer Health Data Privacy Policy outlines how it collects, uses, and discloses Consumer Health Data under Washington and similar state laws.
